To address the growing demand for plasmid DNA, Cobra has embarked on a collaborative project with Cytiva (formerly GE Life Sciences) to develop a second-generation PlasmidSelect resin.
This free one-hour webinar will look at the needs within the plasmid DNA market and how our collaboration has sought to address this market opportunity.
Mark your calendars: Wednesday 6th May @ 10am EDT (3pm BST)
Click here to register today
To address the growing demand for plasmid DNA, Cobra Biologics have embarked on a collaborative project with Cytiva to develop a second generation PlasmidSelect resin based on Cytiva's Capto™ bioprocessing resin. This presentation with look at the needs within the plasmid DNA market and how this collaboration has sought to address this market opportunity.
About the Speaker:
Tony Hitchcock, Technical Director, Cobra Biologics
Tony has over 35 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programs for the development of novel therapeutic products including protein, recombinant virus, bacteriophage and plasmid DNA products.
His current role is based in the commercial group and support external collaboration and outreach activities.
Additionally Tony is currently a member of the BIA Science and Innovation Advisory Committee (SIAC) and of industrial advisory boards for Aston and Loughborough Universities.